† represents p < 0.05 difference from baseline. * represents p < 0.05 difference from KA-L. Table 12 presents serum electrolyte data. Overall MANOVA analysis revealed
a significant time effect (Wilks’ Lambda p = 0.02) with no significant overall interaction (Wilks’ Lambda p = 0.26). Univariate MANOVA analysis revealed some small time SRT2104 research buy effects in chloride levels (p = 0.008) and a trend toward an interaction in potassium levels (p = 0.08) but the small changes observed would have no clinical significance. Finally, Table 12 shows whole blood markers assessed throughout the study. Overall MANOVA revealed no significant time (Wilks’ Lambda p = 0.25) or group x time effects (Wilks’ Lambda p = 0.78). Likewise, no significant interactions were observed among groups in white blood cell count (WBC, p = 0.45), red blood cell count (RBC, p = 0.64), hematocrit (p = 0.65), hemoglobin (p = 0.59), mean corpuscular volume (MCV, p = 0.56), mean corpuscular hemoglobin learn more (MCH, p = 0.44), mean corpuscular hemoglobin concentration (MCHC, p = 0.68), red blood cell distribution width (RBCDW, p = 0.92), or platelet count (p = 0.48). Table 12 Serum electrolyte status Marker N Group Day p-level 0 7 28 Sodium (mmol/L) 11 KA-L 140.1 ± 2.3 139.9 ± 1.1 140.0 ± 1.3 Group 0.98 12 KA-H 139.9 ± 2.3 139.7 ± 2.4 140.3 ± 2.1 Time 0.28 12 CrM
140.8 ± 2.1 139.3 ± 1.4 139.7 ± 1.6 G x T 0.57 Potassium (mmol/L) 11 KA-L 4.54 ± 0.3 4.86 ± 0.4 4.82 ± 0.3 Group 0.65 12 KA-H 4.89 ± 0.5 4.71 ± 0.6 5.00 ± 0.3 Time 0.11 12 CrM 4.74 ± 0.4 mafosfamide 4.93 ± 0.4 4.81 ± 0.4 G x T 0.08 Chloride (mmol/L) 11 KA-L 103.3 ± 2.2 103.0 ± 2.4 103.8 ± 1.9 Angiogenesis inhibitor Group 0.21 12 KA-H 102.4 ± 2.2 101.5 ± 2.2 102.6 ± 2.4 Time 0.008 12 CrM 104.3 ± 2.2 102.3 ± 1.7
103.1 ± 1.8 G x T 0.21 Values are means ± standard deviations. Data were analyzed by MANOVA with repeated measures. Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. Table 13 Whole blood markers Marker N Group Day p-level 0 7 28 WBC (x103/ul) 9 KA-L 5.73 ± 0.6 6.13 ± 0.5 6.17 ± 1.5 Group 0.95 12 KA-H 5.83 ± 1.1 5.76 ± 0.9 6.36 ± 1.1 Time 0.16 12 CrM 5.97 ± 1.2 5.73 ± 1.0 5.98 ± 1.2 G x T 0.45 RBC (x106/ul) 9 KA-L 5.44 ± 0.4 5.38 ± 0.5 5.44 ± 0.3 Group 0.28 12 KA-H 5.10 ± 0.4 5.18 ± 0.3 5.23 ± 0.3 Time 0.91 12 CrM 5.42 ± 0.5 5.41 ± 0.5 5.35 ± 0.7 G x T 0.64 Hematocrit (%) 9 KA-L 48.4 ± 3.4 47.9 ± 4.3 48.1 ± 2.9 Group 0.17 12 KA-H 46.5 ± 3.2 47.0 ± 2.8 47.4 ± 1.8 Time 0.96 12 CrM 45.9 ± 2.3 46.1 ± 2.5 45.2 ± 5.4 G x T 0.65 Hemoglobin (g/dl) 9 KA-L 16.0 ± 1.6 16.0 ± 1.6 16.0 ± 1.2 Group 0.21 12 KA-H 15.2 ± 1.2 15.7 ± 1.0 15.6 ± 0.7 Time 0.60 12 CrM 15.1 ± 0.9 15.2 ± 1.1 14.9 ± 2.0 G x T 0.62 MCV (fL) 9 KA-L 89.0 ± 2.8 88.9 ± 2.9 88.3 ± 2.8 Group 0.10 12 KA-H 91.1 ± 3.5 90.8 ± 3.1 90.7 ± 3.6 Time 0.03 12 CrM 85.4 ± 9.2 85.7 ± 9.5 85.0 ± 9.1 G x T 0.56 MCH (pg/cell) 9 KA-L 29.4 ± 1.5 29.6 ± 1.2 29.3 ± 1.2 Group 0.